RecruitingNot ApplicableNCT07326215

A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+

A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+ in Chinese Critically Ill Patients: a Prospective Randomized Controlled Clinical Trial

Sponsor

Vantive Health LLC

Enrollment

99 participants

Start Date

Dec 11, 2025

Study Type

INTERVENTIONAL

Conditions

Acute Kidney Injury Acute Respiratory Distress Syndrome

Summary

PrismaLung+ is a sterile, single-use medical device aimed at performing partial removal of carbon dioxide (CO2) from the patient's venous blood via diffusion through a membrane. The goal of this prospective, open label, randomized controlled study is to evaluate the efficacy and safety of PrismaLung+ on extracorporeal carbon dioxide removal (ECCO2R) in critically ill patients under invasive mechanical ventilation (IMV). Patients will be randomized to receive either IMV combined with ECCO2R (using PrismaLung+) in the study group or IMV alone in the control group, at a ratio of 2:1.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Age ≥ 18 years old.
Invasive mechanical ventilation patients with PaCO2 \> 50 mmHg and pH \< 7.4 under LPV strategy (RR \< 25/min, DP \< 15 cmH2O).
Expected to be able to tolerate ECCO2R for a minimum of 2h.
Patients signed a written informed consent; if the right to consent cannot be exercised due to loss of decision-making ability or impairment of consciousness, the legal representative or immediate family member must sign the informed consent document after fully understanding the research content.

Exclusion Criteria10

Body weight \< 30 kg.
Has a contraindication for systemic anticoagulation with heparin according to the Investigator.
Patient unable to establish extracorporeal circulation access or has a high risk of establishing such access, as judged by the Investigator.
Allergic to the investigational device/tubing, and/or to the CRRT filters/tubing if combined with CRRT treatment.
Expected to require extracorporeal membrane oxygenator (ECMO) treatment within 24h after enrollment.
Patient's primary disease is expected to worsen rapidly or require other surgical intervention within 24h after enrollment.
Diagnosed as brain dead or in a vegetative state.
Pregnant and/or breastfeeding.
Plans to participate in other device studies within 30 days before screening or during the study period or has completed any clinical drug study within 5 half lives of the investigational drug.
Patients is considered as unsuitable for participating in the study, as judged by the Investigator.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPrismaLung+

PrismaLung+ is a medical device that provides ECCO2R as a stand-alone therapy or in combination with CRRT. The planned treatment duration with PrismaLung+ for patients in the study group is 7 days. However, the Investigator can discontinue PrismaLung+ treatment before 7 days if ECCO2R is no longer required. Following the 7-day treatment period, the Investigator will assess the patient's condition to determine whether to continue ECCO2R. Patients will require systemic anticoagulation with heparin during ECCO2R treatment. Continuous renal replacement therapy may be administered concurrently to patients during the study, if needed, at the discretion of the Investigator. During the study, patients will be given active treatment for their primary disease.

OTHERInvasive Mechanical Ventilation

According to the standard clinical practice of IMV, oral or nasal endotracheal intubation can be used for IMV. The initial mode of IMV and ventilatory parameters will be determined based on the patient's condition, and an appropriate patient-centered LPV approach will be selected to adjust the ventilatory parameters to achieve the study LPV strategy. Appropriate treatments other than ECCO2R will be provided for this group. Continuous renal replacement therapy may be administered concurrently to patients during the study, if needed, at the discretion of the Investigator. During the study, patients will be given active treatment for their primary disease.